The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Cited by (3,140)

Items 401–500 of 3,140

1. Checkpoint Inhibitor–Induced Colitis
   Emanuelle Bellaguarda, Stephen B. Hanauer · 2020 · The American Journal of Gastroenterology
2. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
   Dongkui Song, Thomas B. Powles, Lei Shi, Lirong Zhang, Molly A. Ingersoll, Yong‐Jie Lu · 2019 · The Journal of Pathology
3. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
   Spreafico, A., Heirali, A.A., Araujo, D.V., Tan, T.J., Oliva, M., Schneeberger, P.H.H., Chen, B., Wong, M.K., Stayner, L.-A., Hansen, A.R. et al. · 2023 · Annals of Oncology
4. Cutaneous melanoma and the immunotherapy revolution (Review)
   Giulia Costanza Leonardi, Saverio Candido, Luca Falzone, Demetrios A. Spandidos, Massimo Libra · 2020 · International Journal of Oncology
5. Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer
   Arianna Brevi, Laura Lucia Cogrossi, Giulia Grazia, Desirée Masciovecchio, Daniela Impellizzieri, Lucrezia Lacanfora, Matteo Grioni, Matteo Bellone · 2020 · Frontiers in Immunology
6. Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy
   Jiaao Sun, Feng Chen, Guangzhen Wu · 2023 · The ISME Journal
7. The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy
   Olivier Guipaud, Cyprien Jaillet, K. Clément-Colmou, Agnès François, Stéphane Supiot, Fabien Milliat · 2018 · British Journal of Radiology
8. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study
   Lawson Eng, Rinku Sutradhar, Yue Niu, Ning Liu, Ying Liu, Yosuf Kaliwal, Melanie Powis, Geoffrey Liu, Jeffrey M. Peppercorn, Philippe Lucien Bedard et al. · 2023 · Journal of Clinical Oncology
9. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
   Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari, Giovanni Brandi · 2021 · Frontiers in Oncology
10. The significance of microbiome in personalized medicine
    Ava Behrouzi, Amir Hossein Nafari, Seyed Davar Siadat · 2019 · Clinical and Translational Medicine
11. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy
    Vrishketan Sethi, Gerardo A. Vitiello, Deepak B. Saxena, George Miller, Vikas Dudeja · 2019 · Gastroenterology
12. Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy
    Priya Rangan, Anna Mondino · 2022 · Journal for ImmunoTherapy of Cancer
13. Gut microbiota and immunity relevance in eubiosis and dysbiosis
    Hanan E. Al-Rashidi · 2021 · Saudi Journal of Biological Sciences
14. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer
    Tina Cascone, Annikka Weissferdt, Myrna C. B. Godoy, William N. William, Cheuk Hong Leung, Heather Yan Lin, Sreyashi Basu, Shalini Singh Yadav, Apar Pataer, Kyle Gregory Mitchell et al. · 2021 · Nature Communications
15. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
    Nancy Tray, Jeffrey S. Weber, Sylvia Adams · 2018 · Cancer Immunology Research
16. The cancer-immune dialogue in the context of stress
    Yuting Ma, Guido Kroemer · 2023 · Nature reviews. Immunology
17. The association between gut butyrate‐producing bacteria and non‐small‐cell lung cancer
    Qifeng Gui, Hanyu Li, Ange Wang, Xinxiu Zhao, Zhongju Tan, Lufang Chen, Keying Xu, Chi Xiao · 2020 · Journal of Clinical Laboratory Analysis
18. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment
    Hui Xu, Chenxi Cao, Yuqing Ren, Siyuan Weng, Long Liu, Chunguang Guo, Libo Wang, Xinwei Han, Jianzhuang Ren, Zaoqu Liu · 2022 · Frontiers in Immunology
19. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
    Ebrahimi, Hedyeh, Dizman, Nazli, Meza, Luis, Malhotra, Jasnoor, Li, Xiaochen, Dorff, Tanya, Frankel, Paul, Llamas-Quitiquit, Marian, Hsu, Joann, Zengin, Zeynep B. et al. · 2024 · Nature Medicine
20. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
    Nicolas D. Huyghe, Paméla Baldin, Marc Van den Eynde · 2019 · Gastroenterology report
21. Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
    Michał Szczyrek, Paulina Bitkowska, Patryk Chunowski, Paulina Czuchryta, Paweł Adam Krawczyk, Janusz Milanowski · 2021 · Nutrients
22. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
    Ajeeth Kumar Pingili, Mehdi Chaib, Laura M. Sipe, Emily J. Miller, Bin Teng, Rahul Sharma, Johnathan R. Yarbro, Sarah Asemota, Qusai Al Abdallah, Tahliyah S. Mims et al. · 2021 · Cell Reports
23. Aluminum induced intestinal dysfunction via mechanical, immune, chemical and biological barriers
    Wudi Hao, Chenyu Hao, Chengrong Wu, Yuqing Xu, Cuihong Jin · 2021 · Chemosphere
24. Clinical applications of gut microbiota in cancer biology
    Sunny Hei Wong, Thomas N.Y. Kwong, Chun‐Ying Wu, Jun Qing Yu · 2018 · Seminars in Cancer Biology
25. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis
    Yibin Che, Guoyu Chen, Qianqian Guo, Yourong Duan, Haizhong Feng, Qiang Xia · 2023 · Hepatology
26. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
    Lalani, Aly-Khan A., Xie, Wanling, Braun, David A., Kaymakcalan, Marina, Bossé, Dominick, Steinharter, John A., Martini, Dylan J., Simantov, Ronit, Lin, Xun, Wei, Xiao X. et al. · 2020 · European Urology Oncology
27. Clinical impact of probiotics on the efficacy of anti‐PD‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
    Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya‐Kawano, Yuko, Otsubo, Kohei et al. · 2021 · International Journal of Cancer
28. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy
    Aneta Ševčíková, Nikola Izoldova, Viola Števurková, Barbora Kasperova, Michal Chovanec, Soňa Čierniková, Michal Mego · 2022 · International Journal of Molecular Sciences
29. The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
    Azin Aghamajidi, Saman Maleki Vareki · 2022 · Cancers
30. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome‐driven neoplasms
    Tsuyoshi Hamada, Jonathan Andrew Nowak, Danny A. Milner, Mingyang Song, Shuji Ogino · 2019 · The Journal of Pathology
31. The Urinary Microbiome: Implications in Bladder Cancer Pathogenesis and Therapeutics
    Petar Bajic, Alan J. Wolfe, Gopal Nand Gupta · 2019 · Urology
32. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
    Sara Verdura, Elisabet Cuyàs, Begoña Martı́n-Castillo, Javier Abel Menéndez · 2019 · OncoImmunology
33. Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence
    Antonio Passaro, Gianluca Spitaleri, Bishal Gyawali, Filippo de Marinis · 2019 · Journal of Clinical Oncology
34. Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection
    Geert D’Haens, Christian Jobin · 2019 · Gastroenterology
35. Intestinal microbiota: a new force in cancer immunotherapy
    Zhujiang Dai, Jingqiu Zhang, Qi Wu, Huiwen Fang, Chunfeng Shi, Zhen Li, Chaobiao Lin, Dong Tang, Daorong Wang · 2020 · Cell Communication and Signaling
36. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
    Cogdill, Alexandria P., Gaudreau, Pierre Olivier, Arora, Reetakshi, Gopalakrishnan, Vancheswaran, Wargo, Jennifer A. · 2018 · Trends in Immunology
37. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
    Alessandro Rizzo, Angela Dalia Ricci · 2021 · Expert Opinion on Investigational Drugs
38. Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
    David Jungpa Lee, Howard J. Lee, Jocelyn R. Farmer, Kerry Lynn Reynolds · 2021 · Current Cardiology Reports
39. Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment
    Jiajia Duan, Yu Huang, Xunmin Tan, Tingjia Chai, Jing Wu, Hanping Zhang, Yifan Li, Xi Hu, Peng Zheng, Ping Ji et al. · 2021 · Translational Psychiatry
40. Liver Cancer Immunity
    Sumera Irie Ilyas, Juan Wang, Anthony B. El‐Khoueiry · 2020 · Hepatology
41. Rapamycin modulates tissue aging and lifespan independently of the gut microbiota in Drosophila
    Joseph M. Schinaman, Anil Rana, William W. Ja, Rebecca I. Clark, David W. Walker · 2019 · Scientific Reports
42. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.
    Yuki Katayama, Tadaaki Yamada, Takayuki Shimamoto, M. Iwasaku, Y. Kaneko, J. Uchino, K. Takayama · 2019 · Translational Lung Cancer Research
43. The Cancer Immunotherapy Biomarker Testing Landscape
    Eric E. Walk, Sophia Louise Yohe, Amy Beckman, Andrew E. Schade, Mary M. Zutter, John D. Pfeifer, Anna Belinda Berry · 2019 · Archives of Pathology & Laboratory Medicine
44. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
    Alessandro Rizzo, Giovanni Brandi · 2021 · Cancer Treatment and Research Communications
45. Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties
    Antonio Pellegrino, Gaetano Coppola, Francesco Santopaolo, Antonio Gasbarrini, Francesca Romana Ponziani · 2023 · Nutrients
46. Role of the microbiome in occurrence, development and treatment of pancreatic cancer
    Yi‐Cheng Wang, Gang Yang, Lei You, Jinshou Yang, Mengyu Feng, Jiangdong Qiu, Fangyu Zhao, Yueze Liu, Zhe Cao, Lianfang Zheng et al. · 2019 · Molecular Cancer
47. Next generation probiotics for human health: An emerging perspective
    Jan, Tawseefa, Negi, Rajeshwari, Sharma, Babita, Kumar, Sanjeev, Singh, Sangram, Rai, Ashutosh Kumar, Shreaz, Sheikh, Rustagi, Sarvesh, Chaudhary, Nisha, Kaur, Tanvir et al. · 2024 · Heliyon
48. Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
    Junli Zhao, Alexus Roberts, Zilong Wang, Justin T Savage, Ru‐Rong Ji · 2021 · Neuroscience Bulletin
49. Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice
    Youngmin Yoon, Gihyeon Kim, Bu‐Nam Jeon, Sungsoon Fang, Hansoo Park · 2021 · Cancers
50. The impact of the intestinal microbiota in therapeutic responses against cancer
    Anne‐Gaëlle Goubet, Romain Daillère, Bertrand Routy, Lisa Derosa, Paula M. Roberti, Laurence Zitvogel · 2018 · Comptes Rendus Biologies
51. The Role of Immune Checkpoint Inhibitors in Cancer Therapy
    Ahmed Basudan · 2022 · Clinics and Practice
52. Metabolome–Microbiome Crosstalk and Human Disease
    Kathleen A. Lee‐Sarwar, Jessica Ann Lasky-Su, Rachel S. Kelly, Augusto A. Litonjua, Scott T. Weiss · 2020 · Metabolites
53. Dysbiosis of skin microbiome and gut microbiome in melanoma progression
    Chahrazed Mekadim, Helena Kupcová Skalníková, Jana Čížková, Veronika Cizkova, A Palanová, Vratislav Horák, Jakub Mrázek · 2022 · BMC Microbiology
54. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts
    Xiaowen Huang, Muni Hu, Tiantian Sun, Jiantao Li, Yilu Zhou, Yuqing Yan, Baoqin Xuan, Jilin Wang, Hua Xiong, Linhua Ji et al. · 2023 · Cell Host & Microbe
55. Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
    Jindong Xie, Manqing Liu, Xinpei Deng, Yuhui Tang, Shaoquan Zheng, Xueqi Ou, Hailin Tang, Xiaoming Xie, Minqing Wu, Yutian Zou · 2024 · iMeta
56. Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites
    Yun Teng, Chao Luo, Xiaolan Qiu, Jingyao Mu, Mukesh K. Sriwastva, Qingbo Xu, Minmin Liu, Xin Hu, Fangyi Xu, Lifeng Zhang et al. · 2025 · Nature Communications
57. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy
    Phelps, Catherine M., Willis, Nathaniel B., Duan, Tingting, Lee, Amanda H., Zhang, Yue, Rodriguez J, Daphne M., Pandey, Surya P., Laughlin, Colin R., Rosen, Aaron B.I., McPherson, Alex C. et al. · 2025 · Cell
58. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
    Luisa Chocarro, Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Carlos Hernandez, Gonzalo Fernández, María Jesús García-Granda, Ester Blanco, Ruth Vera, Grazyna T. Kochan et al. · 2020 · Frontiers in Pharmacology
59. Gut Microbial Metabolites Induce Donor-Specific Tolerance of Kidney Allografts through Induction of T Regulatory Cells by Short-Chain Fatty Acids
    Huiling Wu, Julian Singer, Tony Kwan, Yik Wen Loh, Chuanmin Wang, Jian Tan, Yan Jun Li, Christina Lai, Laurence Macia, Stephen I. Alexander et al. · 2020 · Journal of the American Society of Nephrology
60. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
    Ewan Andrew Langan, Victoria Grätz, Judith Allerheiligen, Detlef Zillikens, Jan Rupp, Patrick Andres Maximilian Terheyden · 2020 · The Lancet Oncology
61. Microbiome diurnal rhythmicity and its impact on host physiology and disease risk
    Samuel Philip Nobs, Timur Tuganbaev, Eran Elinav · 2019 · EMBO Reports
62. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice
    Shilong Zhang, Bing Han, Yuqin Mao, Zhengyan Zhang, Zhanming Li, Chao‐Yue Kong, You Wu, Guoqiang Chen, Li‐Shun Wang · 2022 · Gut Microbes
63. Turning cold tumors into hot tumors to ignite immunotherapy
    Yuan‐Tong Liu, Yunlong Wang, Shuo Wang, Jiajun Li, Wei A. He, Xin-Juan Fan, Xiang‐Bo Wan · 2025 · Molecular Cancer
64. RETRACTED ARTICLE: Bacteria eat nanoprobes for aggregation-enhanced imaging and killing diverse microorganisms
    Yunmin Yang, Binbin Chu, Jiayi Cheng, Jiali Tang, Bin Song, Houyu Wang, Yao He · 2022 · Nature Communications · Retracted
65. Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science
    Kentaro Inamura, Tsuyoshi Hamada, Susan Bullman, Tomotaka Ugai, Shinichi Yachida, Shuji Ogino · 2022 · Gut
66. Effect of synbiotic supplementation on immune parameters and gut microbiota in healthy adults: a double-blind randomized controlled trial
    Xiaoqin Li, Shan Hu, Jiawei Yin, Xiaobo Peng, Lei King, Linyan Li, Zihui Xu, Li Zhou, Zhao Peng, Xiaolei Ze et al. · 2023 · Gut Microbes
67. The human microbiome and cancer: a diagnostic and therapeutic perspective
    Shruthi Kandalai, Huapeng Li, Nan Zhang, Haidong Peng, Qingfei Zheng · 2023 · Cancer Biology & Therapy
68. Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment
    Anna Louise Pouncey, Alasdair James Scott, James Leslie Alexander, Julian Roberto Marchesi, James K. Kinross · 2018 · ecancermedicalscience
69. The Crosstalk between Microbiome and Immune Response in Gastric Cancer
    Rihab Nasr, Ali I. Shamseddine, Deborah Mukherji, Farah J. Nassar, Sally Naji Temraz · 2020 · International Journal of Molecular Sciences
70. Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy
    Qiaofeng Li, Yu Chao, Bo Liu, Zhisheng Xiao, Zhijuan Yang, Yuzhe Wu, Zhuang Liu · 2022 · Biomaterials
71. Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice
    Chaonan Sun, Ling Chen, Zhu Shen · 2019 · Saudi Pharmaceutical Journal
72. Trials and tribulations of pancreatic cancer immunotherapy
    Daniel R. Principe, Murray Korc, Suneel Deepak Kamath, Hidayatullah G. Munshi, Ajay Rana · 2021 · Cancer Letters
73. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
    Ashley Mark Hopkins, Ganessan Kichenadasse, Christos Stelios Karapetis, Andrew Rowland, Michael Joseph Sorich · 2020 · Clinical Cancer Research
74. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
    Jennifer Anne Bridge, James Lee, ADIL I. DAUD, James W. Wells, Jeffrey A. Bluestone · 2018 · Frontiers in Medicine
75. The Resistance Mechanisms of Lung Cancer Immunotherapy
    Fen Wang, Shubin Wang, Qing Hua Zhou · 2020 · Frontiers in Oncology
76. Effects of microbiota on anticancer drugs: Current knowledge and potential applications
    Jiayuan Huang, Wenting Liu, Wanying Kang, Yulong He, Ruifu Yang, Xiangyu Mou, Wenjing Zhao · 2022 · EBioMedicine
77. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
    Shuyue Wang, Kun Xie, Tengfei Liu · 2021 · Frontiers in Immunology
78. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
    Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, Gennaro Palmiotti · 2022 · Expert Review of Gastroenterology & Hepatology
79. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications
    Karla A. Lee, Heather May Shaw, Veronique A. Bataille, Paul Nathan, Tim D. Spector · 2020 · European Journal of Cancer
80. Bladder cancer, inflammageing and microbiomes
    Austin Martin, Benjamin Leeland Woolbright, Shahid Umar, Molly A. Ingersoll, John Arthur Taylor · 2022 · Nature Reviews Urology
81. Biology and therapeutic targeting of tumour‐associated macrophages
    Tim Beltraminelli, Michele De Palma · 2020 · The Journal of Pathology
82. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development
    Arielle Elkrief, Reilly Pidgeon, Saman Maleki Vareki, Meriem Messaoudene, Bastien Castagner, Bertrand Routy · 2025 · Nature Reviews Drug Discovery
83. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity
    Glitza, Isabella C., Seo, Yongwoo David, Spencer, Christine N., Wortman, Jennifer R., Burton, Elizabeth M., Alayli, Farah A., Loo, Christopher P., Gautam, Shikha, Damania, Ashish, Densmore, Julie et al. · 2024 · Cancer Discovery
84. Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
    Karolina Kaźmierczak-Siedlecka, Giandomenico Roviello, Martina Catalano, Karol Połom · 2021 · Nutrients
85. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma
    Wind, Thijs T., Gacesa, Ranko, Vich Vila, Arnau, de Haan, Jacco J., Jalving, Mathilde, Weersma, Rinse K., Hospers, Geke A.P. · 2020 · Melanoma Research
86. Interaction between gut microbiota and ethnomedicine constituents
    Xueming Wu, Ren Xiang Tan · 2018 · Natural Product Reports
87. The antitumour effects of caloric restriction are mediated by the gut microbiome
    Mao, Yu-Qin, Huang, Jia-Ting, Zhang, Shi-Long, Kong, Chao, Li, Zhan-Ming, Jing, Hui, Chen, Hui-Ling, Kong, Chao-Yue, Huang, Sheng-Hui, Cai, Pei-Ran et al. · 2023 · Nature Metabolism
88. The Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy
    Romy Aarnoutse, Janine Ziemons, John Penders, Sander S. Rensen, Judith de Vos‐Geelen, Marjolein L. Smidt · 2019 · International Journal of Molecular Sciences
89. The gut microbiome of laboratory mice: considerations and best practices for translational research
    Aaron C. Ericsson, Craig L. Franklin · 2021 · Mammalian Genome
90. State of the Art in the Culture of the Human Microbiota: New Interests and Strategies
    Maryam Tidjani Alou, Sabrina Naud, S. Khelaifia, Marion Bonnet, Jean‐Christophe Lagier, Didier Raoult · 2020 · Clinical Microbiology Reviews
91. Targeting regulation of tryptophan metabolism for colorectal cancer therapy: a systematic review
    Honglian Zhang, Aihua Zhang, Jian-hua Miao, Hui Juan Sun, Guangli Yan, Fangfang Wu, Xijun Wang · 2019 · RSC Advances
92. Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1
    Wei Ma, Lu Zhang, Weilong Chen, Zhaoxia Chang, Juchuanli Tu, Yuanyuan Qin, Yuwen Yao, Jiajun Ding, Jiajun Ding, Siqin Li et al. · 2024 · Protein & Cell
93. Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling
    Erick Marcelo Riquelme, Anirban Maitra, Florencia M. McAllister · 2018 · Cancer Discovery
94. The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment: Chance or Curse?
    Annemieke Smet, Juozas Kupčinskas, Alexander Link, Georgina Louise Hold, Jan Bornschein · 2021 · Cellular and Molecular Gastroenterology and Hepatology
95. The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome
    Keisuke Kosumi, Tsuyoshi Hamada, Hideo Koh, Jennifer Borowsky, Susan Bullman, Tyler S. Twombly, Daniel Nevo, Yohei Masugi, Li Liu, Annacarolina da Silva et al. · 2018 · American Journal Of Pathology
96. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients
    Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiaoyan Si, Xiaotong Zhang, Li Zhang · 2020 · Thoracic Cancer
97. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth
    Alastair M. McKee, Benjamin M. Kirkup, Matthew Madgwick, Wesley J. Fowler, Christopher A. Price, Sally A. Dreger, Rebecca Ansorge, Kate A. Makin, Shabhonam Caim, Gwénaëlle Le Gall et al. · 2021 · iScience
98. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
    Araceli Iglesias-Santamaría · 2020 · Clinical & Translational Oncology
99. A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma
    Mattia Ballerini, Serena Galié, Punit Tyagi, Carlotta Catozzi, Hariam Raji, Amir Nabinejad, Angeli D.G. Macandog, Alessandro Cordiale, Bianca Ionela Slivinschi, Karol K. Kugiejko et al. · 2025 · Nature Biomedical Engineering
100. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
     Tong Xiao, Juyeun Lee, Timothy D. Gauntner, Maria Velegraki, Justin Durla Lathia, Zihai Li · 2024 · Nature reviews. Cancer